#USA #New York #Rosen Law Firm #Baxter International #BAX Investors

Opportunity for Baxter Investors: Join the Class Action

There is a significant opportunity for investors who purchased common stock of Baxter International Inc. (NYSE: BAX) during the class period from February 23, 2022, to July 30, 2025. The Rosen Law Firm, a prominent global investor rights law firm, has announced the initiation of a class action lawsuit centered on alleged securities fraud involving the company. As a potential class member, you are reminded of the impending lead plaintiff deadline set for December 15, 2025.

What This Means for Investors

If you have acquired Baxter common stock during the specified period, you may be eligible for compensation without incurring out-of-pocket fees through a contingency fee agreement. This legal framework allows investors to participate in the litigation without upfront costs, making legal representation accessible.

To actively participate in the class action, interested parties can visit Rosen Law Firm’s submission page or reach out directly to attorney Phillip Kim, who can be contacted via the toll-free number 866-767-3653 or through email at [email protected]. It’s crucial to note that a class action lawsuit has already been filed, and to qualify as the lead plaintiff, one must file a motion with the court by the aforementioned date.

Understanding The Lawsuit

The case stems from allegations that Baxter International misled investors by failing to disclose critical information regarding the Novum LVP (Large Volume Pump). According to the lawsuit, throughout the class period, it is contended that:

1. Systemic Defects: The Novum LVP had serious defects that resulted in malfunctions, such as underinfusion and overinfusion, putting patients at significant risk of injury or even death.
2. Knowledge of Malfunctions: Baxter was reportedly aware of multiple incidents involving device malfunctions and associated patient injuries and deaths due to these defects.
3. Inadequate Responses: The attempts made by Baxter to alert customers about these malfunctions were deemed insufficient, as the underlying design flaws persisted, leading to continued harm.
4. Sales Impacts: Consequently, there was an increased risk that customers would have to withdraw the existing Novum LVPs from service, leading Baxter to halt new sales altogether.
5. Misleading Statements: Baxter's statements regarding the safety, effectiveness, and sales projections related to the Novum LVP were consequently claimed to be materially false and misleading.

When this critical information surfaced, it adversely impacted the stock value, leading to significant losses for investors.

Steps Moving Forward

Those considering joining the class action should act promptly. After filing, plaintiff representation is not guaranteed until the court officially certifies the class. Investors may choose to have counsel of their own selection or opt to remain absent from the class at this point.

The outcome of the case could potentially provide significant financial recovery for investors, particularly noting the impressive track record of the Rosen Law Firm in spearheading successful securities class action settlements, including one that set the record for the largest ever against a Chinese company at the time.

For continued updates regarding this class action and other investor rights matters, follow the Rosen Law Firm on LinkedIn and other social media platforms.

In conclusion, if you have invested in Baxter International stock during the class period, now is the time to seek compensation. Make sure to meet the December 15 deadline to potentially serve as a lead plaintiff in what may become a landmark case for investor rights.